My lab @MBIsg and @NUSMedicine is recruiting a fully-funded postdoc to start in Jan 2026! Interested in cell and tissue mechanics, transcriptional regulation of tissue health, or AI/ML for disease mechanobiology? Come join us in Singapore!
https://t.co/qoZz02LPDY
🚨 REVIEW 🚨
#Ageing alters immune function and cancer outcomes. McAllister et al. explore how age-resolved immunoprofiling and models of ageing haematopoiesis reveal immune dynamics and new paths to optimize cancer therapy across age groups.
https://t.co/iZP1o9PP3f
The goal of a PhD is not to learn some facts or read a few papers or learn a bunch of techniques. The goal of a PhD is to learn independence, problem solving, how to finish things you start, resilience, & gain the ability to adapt & think creatively. Learning these things is hard
Part Three of a series of investigations from my lab (https://t.co/CEZ6FkUCRa) looking at how we can recapitulate cancer-associated fibroblast (CAF) heterogeneity in vitro, is now out in Advanced Healthcare Materials! 👉 https://t.co/MwPYmQo7UV
Temporal dynamics of CLDN18.2 expression following zolbetuximab treatment in advanced gastric cancer - ESMO Gastrointestinal Oncology https://t.co/8lJE4P8Ut1
💡 Scientists at @unil found that glutamine synthesis by CAFs promotes the polarization of pro-tumorigenic TAMs and supports tumor growth by altering TAM composition, highlighting the pivotal role of CAFs in shaping the immunosuppressive TME.
@JExpMed | https://t.co/Rp0o5uMpO8
Foam cells are dysfunctional, lipid-laden macrophages. Data indicate that the events underlying foam cell formation are disease- and microenvironment-specific, opening new avenues for disease-specific biomedical research. Learn more: https://t.co/fY5as53Cub.
Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models https://t.co/1t1peNzFzt
I’m happy to share our latest work on tumour necrosis! During my time in the @megeblad lab, we found that tumour necrosis is not a passive phenomenon secondary to tumour growth, but an active phenomenon driven by neutrophils and NETs! Thread below: (1/13)
https://t.co/Tr0nHLXRzz
Lars Kemp (@kemp_lars) and a team in the @GloerichLab analyzed gastric tumors to identify the molecular changes that contribute to the progression of indolent to aggressive diffuse-type #GastricCancer legions.
🔖 @Gut_BMJ: https://t.co/JQX1EjUy9p